Welcome to Markets Desk, your midday read on what's moving markets and the companies behind them.
Akari Therapeutics is the standout mover this morning, with shares more than doubling in pre-market trading after the biotech released preclinical data showing its antibody-drug conjugate AKTX-one-oh-one works synergistically with a KRAS inhibitor in pancreatic cancer models. That combination approach is exactly what oncology investors have been waiting for, and the market is pricing in the possibility fast.
Shifting to big tech, Satya Nadella is restructuring Microsoft's senior leadership in what amounts to the most significant reorganization in the company's recent history. The move dismantles a management layer that has been in place for decades, consolidating decision-making closer to Nadella himself as Microsoft races to compete with leaner, AI-native rivals. The message from Redmond is clear — speed and technical depth now outrank institutional hierarchy.
And SpaceX scrubbed the latest Starship launch attempt, pushing the window to Friday evening. The timing draws attention given reports of a potential two trillion dollar IPO on the horizon for the company. Every Starship test now carries weight well beyond the engineering milestone — it is increasingly a valuation event.
That's the tape. Markets Desk, signing off the floor.
